WP
Wang Philip Li Executive
Other M
Insider track record CEO Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the complete record of transactions filed by Wang Philip Li, Executive. Director active across 2 companies, notably Shanghai Bio-heart Biological Technology Co., Ltd. - B. Cumulatively, 56 disclosures have been recorded. Activity tracked since 17 April 2026. The latest transaction was disclosed on 10 July 2026 (Purchase). Regulator: HKEX. The full history is free.
Declarations 56 total
10,000 shares @ €0.3205 0.0000% mcap 0.3% of flow Share HKEX:DA20260710E00098 Ideal exit: 6 Apr 2027 (T+270) 10,000 shares @ €0.3589 0.0000% mcap 0.3% of flow Share HKEX:DA20260709E00037 Ideal exit: 5 Apr 2027 (T+270) 10,000 shares @ €0.3465 0.0000% mcap 0.3% of flow Share HKEX:DA20260708E00746 Ideal exit: 4 Apr 2027 (T+270) 10,000 shares @ €0.3579 0.0000% mcap 0.3% of flow Share HKEX:DA20260707E00063 Ideal exit: 3 Apr 2027 (T+270) 10,000 shares @ €0.387 0.0000% mcap 0.4% of flow Share HKEX:DA20260706E00048 Ideal exit: 2 Apr 2027 (T+270) 10,000 shares @ €0.2923 0.0000% mcap 0.3% of flow Share HKEX:DA20260702E00052 Ideal exit: 29 Mar 2027 (T+270) 10,000 shares @ €0.2356 0.0000% mcap 0.2% of flow Share HKEX:DA20260630E00090 Ideal exit: 27 Mar 2027 (T+270) 10,000 shares @ €0.2368 0.0000% mcap 0.2% of flow Share HKEX:DA20260629E00093 Ideal exit: 26 Mar 2027 (T+270) 10,000 shares @ €0.2228 0.0000% mcap 0.2% of flow Share HKEX:DA20260626E00051 Ideal exit: 23 Mar 2027 (T+270) 10,000 shares @ €0.238 0.2% of flow Share HKEX:DA20260625E00037 Ideal exit: 22 Mar 2027 (T+270) 10,000 shares @ €0.2404 0.2% of flow Share HKEX:DA20260624E00027 Ideal exit: 21 Mar 2027 (T+270) 10,000 shares @ €0.2443 0.2% of flow Share HKEX:DA20260623E00688 Ideal exit: 20 Mar 2027 (T+270) 10,000 shares @ €0.2745 0.3% of flow Share HKEX:DA20260622E00011 Ideal exit: 19 Mar 2027 (T+270) 10,000 shares @ €0.2687 0.2% of flow Share HKEX:DA20260618E00035 Ideal exit: 15 Mar 2027 (T+270) 10,000 shares @ €0.2839 0.3% of flow Share HKEX:DA20260617E00070 Ideal exit: 14 Mar 2027 (T+270) 10,000 shares @ €0.2881 0.3% of flow Share HKEX:DA20260616E00048 Ideal exit: 13 Mar 2027 (T+270) 10,000 shares @ €0.2943 0.3% of flow Share HKEX:DA20260612E00384 Ideal exit: 9 Mar 2027 (T+270) 10,000 shares @ €0.2969 0.3% of flow Share HKEX:DA20260615E00033 Ideal exit: 12 Mar 2027 (T+270) 10,000 shares @ €0.29 0.3% of flow Share HKEX:DA20260611E00046 Ideal exit: 8 Mar 2027 (T+270) 10,000 shares @ €0.2987 0.3% of flow Share HKEX:DA20260610E00022 Ideal exit: 7 Mar 2027 (T+270) 10,000 shares @ €0.2942 0.3% of flow Share HKEX:DA20260609E00026 Ideal exit: 6 Mar 2027 (T+270) 10,000 shares @ €0.3054 0.3% of flow Share HKEX:DA20260608E00027 Ideal exit: 5 Mar 2027 (T+270) 10,000 shares @ €0.314 0.3% of flow Share HKEX:DA20260605E00432 Ideal exit: 2 Mar 2027 (T+270) 10,000 shares @ €0.3385 0.0000% mcap 0.3% of flow Share HKEX:DA20260604E00085 Ideal exit: 1 Mar 2027 (T+270) 10,000 shares @ €0.344 0.0000% mcap 0.3% of flow Share HKEX:DA20260604E00084 Ideal exit: 28 Feb 2027 (T+270) 25 of 56 declarations
Load more (31 remaining) About Wang Philip Li Philip Li Wang is an executive at Shanghai Bio-heart Biological Technology Co., Ltd. - B -H Sh.